CROs/Service Providers

Acurian launches consulting services for clinical trial enrollment planning

Friday, May 19, 2017

Acurian, a full-service provider of global patient enrollment and retention solutions and a subsidiary of Pharmaceutical Product Development (PPD), has launched a new consulting offering to aid pharmaceutical sponsors in advance strategic planning for clinical trials enrollment. Acurian Consulting Services provides patient-centric, data-driven insights that help drive protocol design, patient enrollment feasibility, site and country planning, CRO selection and budgeting for central recruitment.

[Read More]

Charles River Laboratories updates oncology business

Wednesday, May 17, 2017

Charles River Laboratories International recently announced updates to its expanding oncology discovery business, including significant additions to its online Tumor Model Compendium. The Compendium provides oncology researchers with a resource to identify and locate targeted suitable patient-derived xenografts (PDXs) based on specific histology and molecular properties, and now includes additional molecular characteristics for syngeneic models.

[Read More]

Thermo Fisher Scientific to acquire Patheon

Tuesday, May 16, 2017

Thermo Fisher Scientific will acquire Patheon, a global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35 per share in cash. The transaction represents a purchase price of approximately $7.2 billion, which includes the assumption of approximately $2 billion of net debt.

[Read More]

INC Research and inVentiv Health to merge

Wednesday, May 10, 2017

INC Research Holdings, a global phase I–IV CRO, and inVentiv Health, a privately held, global CRO and Contract Commercial Organization (CCO), have announced that their Boards of Directors have unanimously approved a definitive merger agreement pursuant to which their businesses would combine in an all-stock transaction, creating a global biopharmaceutical solutions organization.

[Read More]

Avantor to acquire VWR for $6.4B

Friday, May 5, 2017

Avantor, a global supplier of ultra-high-purity materials for the life sciences and advanced technology industries, will acquire VWR, a major global independent provider of product, supply chain and service solutions to laboratory and production customers, for $33.25 in cash per share of VWR common stock, reflecting an enterprise value of approximately $6.4 billion. The purchase price represents an approximate 17% premium to the unaffected closing stock price on May, 2, 2017, the day prior to the start of market speculation regarding a potential sale of VWR. The purchase price also represents an approximate 20% premium to the 30 trading day volume weighted average price (VWAP), and an approximate 24% premium to the 90 trading day VWAP of VWR common stock as of May 2, 2017.

[Read More]